Discontinued — last reported Q2 '17
Morgan Stanley Long-Term Debt - Fair Value increased by 4.1% to $132.48B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 28.2%, from $103.33B to $132.48B. Over 4 years (FY 2021 to FY 2025), Long-Term Debt - Fair Value shows an upward trend with a 14.8% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase relative to book value may indicate rising interest rates or changes in credit risk, while a decrease may suggest favorable refinancing opportunities.
This represents the estimated market value of the company's long-term debt obligations if they were to be settled or tra...
Standard across large-cap pharmaceutical firms, often compared against total debt to assess interest rate sensitivity.
long_term_debt_fair_value| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $76.34B | $75.96B | $70.67B | $68.79B | $78.72B | $86.42B | $87.83B | $86.56B | $93.90B | $95.10B | $97.06B | $107.55B | $103.33B | $112.09B | $125.49B | $127.29B | $132.48B |
| QoQ Change | — | -0.5% | -7.0% | -2.7% | +14.4% | +9.8% | +1.6% | -1.4% | +8.5% | +1.3% | +2.1% | +10.8% | -3.9% | +8.5% | +12.0% | +1.4% | +4.1% |
| YoY Change | — | — | — | — | +3.1% | +13.8% | +24.3% | +25.8% | +19.3% | +10.0% | +10.5% | +24.3% | +10.0% | +17.9% | +29.3% | +18.4% | +28.2% |
We use cookies for analytics. See our Privacy and Cookie Policy.